Literature DB >> 3196151

Dose and sex-dependent disposition of ketoconazole in rats.

P Sjöberg1, L Ekman, T Lundqvist.   

Abstract

The disposition of the antifungal drug ketoconazole was studied in mature (60-day-old) male and female rats given single intravenous doses of 10, 20 or 40 mg/kg body weight. The plasma profiles of ketoconazole were characterized by an initial rapid decline, followed by an apparent zero-order decline and a subsequent first-order elimination phase. In male animals the zero-order phase was less pronounced, resulting in a 3-5 times higher overall rate of elimination. A consequence of the dose-dependent disposition was that a 4-fold increase in dose resulted in a 9- and 17-fold increase in the area under the plasma concentration-time curve (AUC) of females and males, respectively. Terminal half-lives were independent of dose in both sexes. The disproportionate increase in AUC with dose, together with the observation that no intact ketoconazole was excreted in urine and only very small amounts in bile (less than 1% of given dose), suggest that the dose-dependent disposition is caused by saturation of metabolizing enzymes. These enzymes are most likely under the influence of androgens, since the capacity of males to eliminate ketoconazole was reduced by castration and in females this capacity was increased by testosterone treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3196151     DOI: 10.1007/bf00570136

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  18 in total

1.  The effect of chronic oral ketoconazole on in vivo drug metabolism in the rat.

Authors:  L Jiritano; A Bortolotti; M Bonati
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1986-11

Review 2.  Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis.

Authors:  D Feldman
Journal:  Endocr Rev       Date:  1986-11       Impact factor: 19.871

3.  Influence of food on the pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock; M D Ene; E M Johnson; M R Potten; M D Richardson; P J Williamson
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Micro-determination of ketoconazole in plasma or serum by high-performance liquid chromatography.

Authors:  N R Badcock
Journal:  J Chromatogr       Date:  1984-03-09

Review 5.  Sex-related differences in drug metabolism.

Authors:  R Kato
Journal:  Drug Metab Rev       Date:  1974       Impact factor: 4.518

6.  Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers.

Authors:  Y C Huang; J L Colaizzi; R H Bierman; R Woestenborghs; J Heykants
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

7.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Site of action of low dose ketoconazole on androgen biosynthesis in men.

Authors:  R J Santen; H Van den Bossche; J Symoens; J Brugmans; R DeCoster
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

Review 9.  Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action.

Authors:  H Vanden Bossche
Journal:  Curr Top Med Mycol       Date:  1985

10.  Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients.

Authors:  R De Coster; I Caers; M C Coene; W Amery; D Beerens; C Haelterman
Journal:  Clin Endocrinol (Oxf)       Date:  1986-06       Impact factor: 3.478

View more
  1 in total

1.  A microRNA or messenger RNA point of departure estimates an apical endpoint point of departure in a rat developmental toxicity model.

Authors:  Kamin J Johnson; Eduardo Costa; Valerie Marshall; Shreedharan Sriram; Anand Venkatraman; Kenneth Stebbins; Jessica LaRocca
Journal:  Birth Defects Res       Date:  2022-05-21       Impact factor: 2.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.